Main cancers (summary list)

Five-year relative survival by HSE area of residence (diagnosis years 2003-2007)

			Five-year relative survival (with 95% confidence interval) by HSE area of residence (2003-2007)
Cancer type	Sex	Age at diagnosis	Total	Dublin /	Dublin /	South	West
(EUROCARE definition)				Mid Leinster	North East


all except NMSC'	both	all 15-99	59.5%	61.9%	58.7%	58.4%	58.4%
(ICD10 C00-C97 ex C44)		(unstandardized)	(58.9-60%)	(60.9-62.8%)	(57.5-59.8%)	(57.4-59.4%)	(57.3-59.5%)


all except NMSC	male	all 15-99	58.5%	61.1%	57.5%	57.2%	57.7%
(ICD10 C00-C97 ex C44)		(unstandardized)	(57.7-59.2%)	(59.6-62.5%)	(55.8-59.1%)	(55.7-58.5%)	(56.1-59.2%)


all except NMSC	female	all 15-99	60.5%	62.7%	59.8%	59.8%	59.2%
(ICD10 C00-C97 ex C44)		(unstandardized)	(59.7-61.2%)	(61.3-63.9%)	(58.2-61.3%)	(58.3-61.2%)	(57.6-60.7%)


head & neck	both	all 15-99	50.3%	51.6%	48.4%	48.6%	50.5%
(ICD10 C01-C06,C09-C13)		(unstandardized)	(46.1-54.4%)	(44.2-58.5%)	(38.5-57.9%)	(40.0-56.8%)	(42.5-58.3%)


oesophagus	both	all 15-99	15.8%	18.8%	17.7%	15.2%	11.6%
(ICD10 C15)		(unstandardized)	(13.3-18.6%)	(13.9-24.2%)	(12.2-24.1%)	(11.0-20.0%)	(7.0-17.5%)


stomach	both	all 15-99	23.9%	24.7%	26.1%	20.6%	22.0%
(ICD10 C16)		(unstandardized)	(21.4-26.4%)	(20.3-29.3%)	(21.0-31.5%)	(16.2-25.3%)	(17.2-27.1%)


colorectal	both	all 15-99	57.6%	59.3%	58.2%	57.2%	55.6%
(ICD10 C18-C21)		(unstandardized)	(56.0-59.1%)	(56.2-62.3%)	(54.7-61.5%)	(54.3-60.0%)	(52.4-58.7%)

colorectal	both	all 15-99	57.0%	59.1%	57.4%	56.6%	54.6%
(ICD10 C18-C21)		(age-standardized)#	(53.7-60.2%)	(52.6-65.1%)	(50.1-64.3%)	(50.4-62.4%)	(47.7-60.9%)


			Five-year relative survival (with 95% confidence interval) by HSE area of residence (2003-2007)
Cancer type	Sex	Age at diagnosis	Total	Dublin /	Dublin /	South	West
(EUROCARE definition)				Mid Leinster	North East


colon	both	all 15-99	57.7%	56.8%	59.1%	57.6%	57.4%
(ICD10 C18)		(unstandardized)	(55.7-59.6%)	(52.8-60.6%)	(54.7-63.3%)	(53.8-61.3%)	(53.5-61.2%)


rectum/anus	both	all 15-99	57.4%	63.7%	57.0%	56.6%	52.2%
(ICD10 C19-C21)		(unstandardized)	(54.8-59.8%)	(58.9-68.4%)	(51.4-62.4%)	(52.0-60.9%)	(46.8-57.4%)


pancreas	both	all 15-99	6.2%	7.8%	4.8%	5.7%	5.6%
(ICD10 C25)		(unstandardized)	(4.6-8.0%)	(4.9-11.6%)	(2.1-9.2%)	(3.3-9.1%)	(2.9-9.6%)


liver	both	all 15-99	12.9%	14.2%	20.7%	8.4%	9.3%
(ICD10 C22)		(unstandardized)	(9.4-17.0%)	(7.1-24.0%)	(12.7-30.4%)	(3.6-16.1%)	(4.5-16.5%)


larynx	both	all 15-99	57.9%	67.2%	48.1%	57.8%	55.2%
(ICD10 C32)		(unstandardized)	(51.8-63.7%)	(56.0-77.0%)	(35.2-60.4%)	(46.7-67.9%)	(41.0-68.2%)


lung & trachea	both	all 15-99	11.7%	13.3%	12.7%	8.8%	12.2%
(ICD10 C33-C34)		(unstandardized)	(10.7-12.7%)	(11.4-15.2%)	(10.7-14.7%)	(7.1-10.6%)	(10.2-14.3%)

lung & trachea	both	all 15-99	12.7%	13.8%	13.6%	9.9%	13.4%
(ICD10 C33-C34)		(age-standardized)#	(10.5-15.2%)	(9.6-18.8%)	(9.1-18.9%)	(6.0-14.7%)	(9.0-18.4%)


bone & cartilage	both	all 15-99	64.4%	48.9%	75.5%	61.1%	61.3%
(ICD10 C40-C41)		(unstandardized)	(52.9-74.2%)	(27.1-68.3%)	(48.7-91.0%)	(41.0-76.6%)	(39.8-77.7%)


			Five-year relative survival (with 95% confidence interval) by HSE area of residence (2003-2007)
Cancer type	Sex	Age at diagnosis	Total	Dublin /	Dublin /	South	West
(EUROCARE definition)				Mid Leinster	North East


melanoma of skin	both	all 15-99	86.6%	88.5%	84.1%	89.4%	82.1%
(ICD10 C43)		(unstandardized)	(84.1-88.8%)	(84.4-91.9%)	(78.1-89.1%)	(84.5-93.5%)	(76.0-87.3%)

melanoma of skin	both	all 15-99	86.0%	86.9%	81.9%	87.9%	81.1%
(ICD10 C43)		(age-standardized)#	(80.5-90.5%)	(77.4-93.9%)	(68.5-91.5%)	(76.7-95.6%)	(68.2-90.4%)


soft tissue	both	all 15-99	63.3%	68.3%	74.0%	46.6%	59.8%
(ICD10 C47 & C49)		(unstandardized)	(56.1-70.0%)	(55.7-78.9%)	(61.2-83.9%)	(32.1-60.6%)	(43.0-75.0%)


breast	female	all 15-99	85.0%	87.0%	84.4%	84.5%	83.6%
(ICD10 C50)		(unstandardized)	(83.8-86.1%)	(84.8-88.8%)	(81.7-86.8%)	(82.1-86.6%)	(80.9-86.0%)

breast	female	all 15-99	81.8%	83.3%	80.3%	82.8%	80.1%
(ICD10 C50)		(age-standardized)#	(78.6-84.7%)	(77.4-88.4%)	(73.0-86.5%)	(76.6-88.1%)	(73.2-86.4%)


cervix uteri	female	all 15-99	66.2%	65.7%	65.8%	69.4%	63.7%
(ICD10 C53)		(unstandardized)	(62.2-69.8%)	(58.6-72.0%)	(57.4-73.0%)	(62.0-75.8%)	(54.2-71.9%)

cervix uteri	female	all 15-99	55.8%	53.6%	-	59.3%	56.6%
(ICD10 C53)		(age-standardized)#	(45.6-66.2%)	(35.7-72.4%)		(40.5-77.0%)	(32.7-77.0%)


corpus uteri	female	all 15-99	77.3%	79.2%	76.5%	75.7%	77.0%
(ICD10 C54)		(unstandardized)	(73.6-80.6%)	(72.4-85.0%)	(67.8-83.6%)	(68.5-81.9%)	(69.1-83.7%)


ovary & uterine adnexa	female	all 15-99	38.9%	42.6%	37.7%	41.1%	32.9%
(ICD10 C56 & C57.0-57.7)~		(unstandardized)	(35.6-42.1%)	(36.5-48.7%)	(30.6-44.8%)	(34.8-47.3%)	(26.7-39.2%)


			Five-year relative survival (with 95% confidence interval) by HSE area of residence (2003-2007)
Cancer type	Sex	Age at diagnosis	Total	Dublin /	Dublin /	South	West
(EUROCARE definition)				Mid Leinster	North East


prostate	male	all 15-99	92.8%	95.4%	92.8%	90.8%	91.6%
(ICD10 C61)		(unstandardized)	(91.5-94.0%)	(93.0-97.7%)	(89.8-95.6%)	(88.2-93.2%)	(88.8-94.0%)

prostate	male	all 15-99	89.9%	91.7%	87.9%	87.7%	89.0%
(ICD10 C61)		(age-standardized)#	(86.7-92.8%)	(85.5-97.6%)	(80.0-94.8%)	(81.7-93.1%)	(83.1-94.2%)


testis	male	all 15-99	97.0%	96.0%	96.7%	96.8%	97.5%
(ICD10 C62)		(unstandardized)	(95.0-98.3%)	(89.8-98.7%)	(92.5-98.7%)	(92.8-98.7%)	(93.1-99.3%)


kidney & related	both	all 15-99	57.5%	57.1%	55.6%	56.9%	59.7%
(ICD10 C64-66 & C68)		(unstandardized)	(54.0-60.8%)	(50.1-63.7%)	(47.6-63.1%)	(50.4-63.3%)	(52.9-66.0%)


bladder	both	all 15-99	69.4%	70.9%	69.3%	69.3%	66.2%
(ICD10 C67)		(unstandardized)	(65.9-72.7%)	(64.6-76.8%)	(61.8-76.2%)	(62.7-75.6%)	(58.8-73.0%)


brain	both	all 15-99	19.1%	22.3%	19.3%	18.0%	15.7%
(ICD10 C71)		(unstandardized)	(16.3-22.0%)	(17.0-28.2%)	(13.9-25.5%)	(13.0-23.6%)	(10.8-21.5%)


thyroid	both	all 15-99	84.7%	85.6%	85.5%	76.2%	85.2%
(ICD10 C73)		(unstandardized)	(78.7-89.4%)	(76.0-92.2%)	(70.0-94.7%)	(59.7-87.8%)	(73.6-92.9%)


Hodgkin lymphoma	both	all 15-99	87.5%	90.8%	86.0%	82.2%	84.9%
(ICD10 C81)		(unstandardized)	(83.2-91.0%)	(83.3-95.5%)	(74.1-93.2%)	(72.9-89.0%)	(75.2-91.4%)


			Five-year relative survival (with 95% confidence interval) by HSE area of residence (2003-2007)
Cancer type	Sex	Age at diagnosis	Total	Dublin /	Dublin /	South	West
(EUROCARE definition)				Mid Leinster	North East


non-Hodgkin lymphoma	both	all 15-99	67.7%	67.7%	69.2%	64.4%	68.3%
(ICD10 C82-C85 & C96)		(unstandardized)	(64.9-70.3%)	(62.2-72.7%)	(63.3-74.5%)	(59.1-69.5%)	(62.8-73.4%)


multiple myeloma	both	all 15-99	41.9%	46.7%	33.5%	38.3%	47.0%
(ICD10 C90)		(unstandardized)	(37.1-46.7%)	(37.0-56.2%)	(23.2-44.5%)	(29.6-47.2%)	(38.3-55.7%)


leukaemia	both	all 15-99	59.4%	63.7%	63.7%	52.8%	55.3%
(ICD10 C91-C95)		(unstandardized)	(56.0-62.7%)	(57.7-69.4%)	(56.4-70.5%)	(46.1-59.2%)	(48.2-62.0%)

Footnotes:

# Age-standardized figures (presented for the more common cancers) use the standard patient population proposed for this cancer by:

Corazziari I., Quinn M. & Capocaccia R. 2004. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 40: 2307-2316.

Exclusions (as in EUROCARE except for bladder):

Patients aged <15 or >99 at diagnosis; death-certificate-only (DCO) and autopsy-only cases; second or subsequent malignancies in the same patient

(or the less serious of two or more synchronously-diagnosed malignancies); in situ carcinomas and tumours of uncertain behaviour (both INCLUDED for bladder by EUROCARE but not here).

‘All-cancer figures exclude non-melanoma skin cancers (NMSC), which are rarely fatal

~ Definition of cancer of the ovary and uterine adnexa used here & in EUROCARE-4 = ICD10 codes C56 and C57.0-C57.7

with the exception of 'borderline' morphologies (not considered malignant in ICDO3).

- = insufficient data